


A new way to offer the care your patients rely on

Treatment in minutes, not hours


PHESGO® is a new way to approach treatment - a combination of PERJETA® and Herceptin®, in one ready-to-use, fixed-dose SC treatment¹⁻⁴

Loading dose

PERJETA + Herceptin IV




PHESGO



Maintenance doses

PERJETA + Herceptin IV




PHESGO



 PERJETA + Herceptin IV administration  PHESGO administration  Observation time

Delivering the results expected from the treatment you know

In the FeDeriCa study, **tpCR were high and almost identical** between treatment arms, suggesting similar efficacy (PHESGO 59.7%; P + H IV 59.5%)⁴



The safety profile of PHESGO in FeDeriCa was overall consistent to the known safety profile of intravenous PERJETA in combination with Herceptin³⁻⁵

tpCR: total pathological complete response rate

Important Safety Information:


If a patient becomes pregnant while receiving PHESGO, or within 7 months following the last dose of PHESGO, please immediately report pregnancy to the Hong Kong Drug Safety Unit at hong_kong.drug_safety@roche.com. Additional information will be requested during a PHESGO-exposed pregnancy and the first year of the infant's life. This will enable Roche to better understand the safety of PHESGO and to provide appropriate information to health authorities, healthcare providers, and patients. For additional information, please refer to the local PHESGO prescription information.

Faster, more comfortable care that helps patients feel less like patients⁵

In the PHranceSCa study

▶ **85% of patients** preferred PHESGO over PERJETA and Herceptin IV⁵

Main reasons for preference were:



▶ More patients were “very satisfied” or “satisfied” with PHESGO (**88%**) vs. PERJETA and Herceptin IV (**68%**)⁵

Releasing resources and freeing staff to make the best use of their time

▶ PHESGO could reduce: *⁶⁻⁹




▶ Shorter chair times are expected to improve patient flow, potentially **allowing greater access** and shortening **waiting lists**⁶

* Time and resource savings extrapolated from time and motion studies with Herceptin SC vs Herceptin IV⁶⁻⁹

Other perceived benefits include:⁵





http://bit.ly/Roche_Phesgo_Pi

Please use the QR code/click on the link for the latest Prescribing Information (PI).
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Please read full prescribing information before usage.

⏪ **Details of Permission or License Number with date:**
Permission No. IMP/BIO/21/000082 dated 01-Oct-2021

Date of Revision:
Current at January 2022, Version 2.0
M-IN-00003036

Disclaimer:
© = Registered Trade Mark F. Hoffmann - La Roche Limited, Basel, Switzerland.
For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.
Full prescribing information available on request.
For scientific information on Roche Medicinal Product please write to india.medinfo@roche.com
For all Adverse Events/Special Situation Reports with Roche Medicinal Product please report the same to india.drugsafety@roche.com within one business day/24 hours.

Date of Expiry: 28/07/2024



Roche Products (India) Pvt. Ltd,
146-B, 166 A, Unit No. 7, 8, 9, 8th Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg,
Ghatkopar, Mumbai - 400 086. Maharashtra. India
Tel No. +91 22 50457300; Fax No, +91 22 50457301